Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 195

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 195
---
 bearing cash account. In September 2023, we further instructed Continental to move the funds held in the Trust Account to an interest bearing bank deposit program until the earlier of the consummation of a business combination or the liquidation of the Company. As a result of these changes, we will have received less interest on the funds held in the Trust Account than we would have if we had not liquidated such assets. As a result, our public stockholders will receive a lower amount upon any redemption or liquidation of the Company as compared to what they would have received had the investments not been so liquidated.

The unaudited pro forma financial information included elsewhere in this proxy statement/prospectus may not be indicative of the Combined Company’s actual financial position or what results of operations would have been.

The unaudited pro forma financial information in this proxy statement/prospectus is presented for illustrative purposes only, has been prepared based on a number of assumptions and is not necessarily indicative of what the combined company’s actual financial position or results of operations would have been had the Business Combination been completed on the dates indicated. The unaudited pro forma condensed combined financial information does not reflect any of the benefits that the combined companies may achieve as a result of the Business Combination or the costs to combine Iris and Liminatus or the costs necessary to achieve these benefits. See “ Unaudited Pro Forma Condensed Combined Financial Information ”.

<div align='center'>84</div>

TABLE OF CONTENTS

The future exercise of registration rights may adversely affect the market price of the ParentCo Common Stock after the Business Combination.

ParentCo’s common stock owned by certain Liminatus Members, the PIPE Investor, the Sponsor, and Cantor Fitzgerald & Co. or their transferees will be subject to the Registration Rights Agreement that provides for the registration for resale of ParentCo’s common stock held by the parties to the Registration Rights Agreement or their transferees. The parties to the Registration Rights Agreement are expected to own approximately 72% of ParentCo’s common stock following the closing of the Business Combination assuming no redemptions. Sales of securities pursuant to this agreement may substantially depress the market price of ParentCo’s common stock.

In connection with the PIPE Equity Investment, ParentCo will grant the PIPE Investor certain customary registration rights as described under “Registration Rights Agreement”.

Each of Iris and Liminatus have incurred and will incur substantial costs in connection with the Business Combination and related transactions, such as legal, accounting, consulting and financial advisory fees.

Each